



DTW

Atty. Docket No. VAN67 P-329

CERTIFICATE OF MAILING

I hereby certify that this paper, together with all enclosures identified herein, are being deposited with the United States Postal Service as first class mail, addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450, on the date indicated below.

May 1, 2007  
Date

Melanie S. Jernberg  
Melanie S. Jernberg

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1615  
Applicant : George F. Vande Woude et al.  
Appln. No. : 10/563,616  
Filing Date : August 9, 2006  
For : INHIBITION OF TUMOR ANGIOGENESIS BY COMBINATION OF  
THROMBOSPONDIN-1 AND INHIBITORS OF VASCULAR  
ENDOTHELIAL GROWTH FACTOR

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.97(b)

Pursuant to 37 CFR §§1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO-1449. This Information Disclosure Statement is being filed more than three months after the filing date of the above-referenced application but, to the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign patent documents and non-patent literature are attached. As the Office has waived the requirement under 37 CFR §1.98(a)(2)(i) for submitting a copy of each cited U.S. patent, copies of the listed U.S. patents are not included with the submission of attached Form PTO 1449. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

Applicant : George F. Vande Woude et al.  
Appln. No. : 10/563,616  
Page : 2

The listed documents were cited in the European Search Report which issued from a corresponding International Patent Application. A copy of the European Search Report is included herewith. The European Search Report is not a reference, and Applicants do not necessarily subscribe to any of the statements contained therein.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 16-2463.

Respectfully submitted,

May 1, 2007

Date



Marcus P. Dolce, Registration No. 46 073  
Price, Heneveld, Cooper, DeWitt & Litton, LLP  
695 Kenmoor, S.E.  
Post Office Box 2567  
Grand Rapids, MI 49501  
(616) 949-9610

MPD/msj

**FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)



**ATTY. DOCKET NO.**  
VAN67 P-329

**SERIAL NO.** 10/563, 616

**APPLICANT(S)**  
George F. Vande Woude et al.

**FILING DATE**  
August 9, 2006

**GROUP**  
1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPRO- PRIATE
	5 6 3 9 7 2 5	06/17/1997	O'Reilly et al.			
	6 5 7 6 6 3 2	06/10/2003	Goldstein et al.			
	5 9 9 7 8 6 8	12/07/1999	Goldberg et al.			
	5 7 0 7 6 2 4	01/13/1998	Nickoloff et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA- TION
						Y N
	0 1 6 6 1 4 4	09/13/01	PCT			
	0 2 0 7 6 4 9 6	10/03/02	PCT			
	0 3 0 1 8 7 4 8	03/06/03	PCT			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL	
	Allegrini, G. et al., "The Angiogenesis Inhibitor Thrombospondin-1 Plus Irinotecan Significantly Inhibit Tumor Growth in Human Colon Tumor Bearing Nude Mice," Proceedings of the American Association for Cancer Research, Volume 41, March 2000, page 813

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE</b> <b>(Rev. 2-32) PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> VAN67 P-329	<b>SERIAL NO.</b> 10/563, 616
	<b>APPLICANT(S)</b> George F. Vande Woude et al.	
	<b>FILING DATE</b> August 9, 2006	<b>GROUP</b> 1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPRO- PRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA- TION
						Y N
	0 2 1 8 3 8 0	03/07/02	PCT			
	0 2 1 8 3 7 9	03/07/02	PCT			
	9 9 4 3 3 1 1	09/02/99	PCT			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL	
	F.Y.F.L. De Vos et al., "A phase I dose escalating study of the angiogenesis inhibitor thrombospondin-1 mimetic (abt-510) in patients with advanced cancer," European Journal of Cancer, Volume 38, November 2002, pages S78-S79
	Armstrong, L.C. et al., "Thrombospondins 1 and 2 function as inhibitors of angiogenesis," Matrix Biology, Volume 22, March 2003, pages 63-71
	Guo, N-H. et al., "Antiproliferative and Antitumor Activities of D-Reverse Peptides Derived From the Second Type-1 Repeat of Thrombospondin-1," Journal of Peptide Research, Volume 50, September 1997, pages 210-221

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



<p><b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE</b>  <b>(Rev. 2-32) PATENT AND TRADEMARK OFFICE</b></p> <p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p style="text-align: center;">(Use several sheets if necessary)</p>	<p><b>ATTY. DOCKET NO.</b> VAN67 P-329</p>	<p><b>SERIAL NO.</b> 10/563, 616</p>
<p><b>APPLICANT(S)</b> George F. Vande Woude et al.</p>		
<p><b>FILING DATE</b> August 9, 2006</p>		<p><b>GROUP</b> 1615</p>

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPRO- PRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA- TION	
							Y	N

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL		
		Streit, Michael et al., "Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas," American Journal of Pathology, Volume 155, August 1999, pages 441-452
		Reiher, Frank K. et al., "Inhibitions of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics," International Journal of Cancer, Volume 98, April 10, 2002, pages 682-689
		Feige, JJ, "The thrombospondins: "Multimodular proteins with angiogenesis inhibiting effects," Pathologie Biologie, Volume 47, No. 4, April 1999, pages 339-344
		Lawler, Jack, "Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth," Journal of Cellular and Molecular Medicine," Volume 6, January 2002, pages 1-12
		Henkin, Jack et al., "Tumor inhibition by anti-angiogenic TSP-1 mimetic peptides," Proceedings of the American Association for Cancer Research Annual Meeting, Volume 43, March 2002, page 180

<p><b>EXAMINER</b></p>	<p><b>DATE CONSIDERED</b></p>
<p>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

<p><b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE</b>  <b>(Rev. 2-32) PATENT AND TRADEMARK OFFICE</b></p> <p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p style="text-align: center;">(Use several sheets if necessary)</p>	<p><b>ATTY. DOCKET NO.</b> VAN67 P-329</p>	<p><b>SERIAL NO.</b> 10/563, 616</p>
<p><b>APPLICANT(S)</b> George F. Vande Woude et al.</p>		
<p><b>FILING DATE</b> August 9, 2006</p>		<p><b>GROUP</b> 1615</p>

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPRO- PRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA- TION	
							Y	N

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

EXAMINER INITIAL		
		Vailhe, Bruno et al., "Thrombospondins as anti-angiogenic therapeutic agents," Current Pharmaceutical Design, Volume 9, 2003, pages 583-588
		Iruela-Arispe, M. L. et al., "Inhibition of Angiogenesis by Thrombospondin-1 is Mediated by 2 Independent Regions Within the Type 1 Repeats," American Heart Association, Volume 100, September 28, 1999, pages 1423-1431
		Database WPI, Section Ch, Week 200347, Derwent Publications
		Database WPI, Section Ch, Week 200364, Derwent Publicaitons
		Zhang, Yu Wen et al., "Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation," Proceedings of the National Academy of Sciences of the United States of America, Volume 100, October 28, 2003, pages 12718-12723

<p><b>EXAMINER</b></p>	<p><b>DATE CONSIDERED</b></p>
<p>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	